Current approaches to the treatment of Parkinson's Disease

被引：92

作者：

Ellis, J. Michael ^{[1
]}

Fell, Matthew J. ^{[2
]}

机构：

[1] Merck & Co Inc, Dept Discovery Chem, 33 Ave Louis Pasteur, Boston, MA 02115 USA

[2] Merck & Co Inc, Dept Discovery Neurosci, 33 Ave Louis Pasteur, Boston, MA 02115 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2017年 / 27卷 / 18期

关键词：

Parkinson's Disease; Neurodegeneration; Symptomatic; Disease modification; Dopamine; alpha-Synuclein; MYELOPEROXIDASE; PRELADENANT; INHIBITORS; THERAPIES; MECHANISM; LEVODOPA; SAFETY; TRIAL;

D O I：

10.1016/j.bmcl.2017.07.075

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Parkinson's Disease (PD) is the second most common neurodegenerative disorder. Clinical approaches to manage PD include symptomatic therapies, serving to compensate for the effects of dopaminergic neuronal deficits, as well as more recently a move toward disease modification, with the goal of slowing or stopping disease progression. This perspective surveys the approved therapies for PD treatment as well as provides a view of the ongoing clinical approaches aimed at improving outcomes for PD patients. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：4247 / 4255

页数：9

共 35 条

[1]

[Anonymous], 2003, COCHRANE DATABASE SY

[2] O-METHYLATION OF EPINEPHRINE AND OTHER CATECHOLS INVITRO AND INVIVO [J].

AXELROD, J .

SCIENCE, 1957, 126 (3270) :400-401

[3]

Blasczyk JW, 2016, FRONT NEUROSCI, V10, P1

[4] EFFICACY AND SAFETY OF NOVEL DOPAMINE SEROTONIN STABILIZER RP 5063 IN ACUTE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER [J].

Cantillon, Marc .

SCHIZOPHRENIA RESEARCH, 2014, 153 :S22-S22

[5] Pharmacological Treatment of Parkinson Disease A Review [J].

Connolly, Barbara S. ;

Lang, Anthony E. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (16) :1670-1683

[6] EXCITATION-MEDIATING AND INHIBITION-MEDIATING DOPAMINE-RECEPTORS - NEW CONCEPT TOWARDS A BETTER UNDERSTANDING OF ELECTROPHYSIOLOGICAL, BIOCHEMICAL, PHARMACOLOGICAL, FUNCTIONAL AND CLINICAL DATA [J].

COOLS, AR ;

VANROSSUM, JM .

PSYCHOPHARMACOLOGIA, 1976, 45 (03) :243-254

[7]

Daniely A., 2016, PARKINSONS DIS, V49, P1

[8] Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease [J].

Dong, Jie ;

Cui, Yanhua ;

Li, Song ;

Le, Weidong .

CURRENT NEUROPHARMACOLOGY, 2016, 14 (04) :339-355

[9] Afatinib: First Global Approval [J].

Dungo, Rosselle T. ;

Keating, Gillian M. .

DRUGS, 2013, 73 (13) :1503-1515

[10] Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B [J].

Edmondson, Dale E. ;

Binda, Claudia ;

Mattevi, Andrea .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2007, 464 (02) :269-276

← 1 2 3 4 →